266 related articles for article (PubMed ID: 29582406)
1. Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Cooper K; Frampton G; Harris P; Rose M; Chorozoglou M; Pickett K
Pharmacoeconomics; 2018 May; 36(5):545-553. PubMed ID: 29582406
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
4. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Rose M; Shepherd J; Harris P; Pickett K; Lord J
Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
Han S; Kim S; Kim H; Suh HS
Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
[No Abstract] [Full Text] [Related]
6. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
8. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Otten T; Riemsma R; Wijnen B; Armstrong N; Stirk L; Gordon C; Ramaekers B; Kleijnen J; Joore M; Grimm S
Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
[TBL] [Abstract][Full Text] [Related]
10. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
13. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
15. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].
Kolbin AS; Avdeev SN; Zhuravleva MV; Gomon YM; Balykina YE; Matveyev NV; Proskurin MA; Fedosenko SV
Ter Arkh; 2019 Dec; 91(12):47-56. PubMed ID: 32598589
[TBL] [Abstract][Full Text] [Related]
18. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
19. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for the treatment of severe persistent allergic asthma.
Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]